Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to shrink breast tumors before surgery

NCT ID NCT07492394

Recruiting now Disease control Sponsor: Hebei Medical University Fourth Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial tests whether adding entinostat to a two-drug regimen (dalpiciclib and letrozole) before surgery can better shrink tumors in women with HR-positive, HER2-negative early breast cancer. Sixty participants will receive either the three-drug combo or the standard two-drug combo for six cycles before surgery. The study measures how many patients have a complete or partial response, and how many achieve a pathological complete response (no cancer left in breast or lymph nodes).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dalpiciclib, entinostat, and letrozole
What this could lead to
If this works, it could point toward a more effective pre-surgery treatment for HR+/HER2- early breast cancer, potentially improving tumor shrinkage and surgical outcomes.
What could go wrong
This is a small, early-phase (Phase 2) study with only 60 participants, so results may not apply to all patients. Adding entinostat may increase side effects, and the benefit over standard therapy is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

  • The Fourth Hospital of Hebei Medical University

    RECRUITING

    Shijiazhuang, Hebei, 050000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.